The changing paradigm of colorectal cancer therapy: the impact of vascular endothelial growth factor and epidermal growth factor and epidermal growth factor receptor inhibition. Introduction.
Chase
Judy L
JL
Clinical Pharmacy Services, Division of Pharmacy, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA. jchase@mdanderson.org
D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000503:physiopathology; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D006801:Humans; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
D000970:Antineoplastic Agents; D042461:Vascular Endothelial Growth Factor A; D066246:ErbB Receptors